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The mechanism of client protein activation by Hsp90 is enigmatic, and it is uncertain whether Hsp90
employs a common route for all proteins. Using a mutational analysis approach, we investigated the activation
of two types of client proteins, glucocorticoid receptor (GR) and the kinase v-Src by the middle domain of
Hsp90 (Hsp90M) in vivo. Remarkably, the overall cellular activity of v-Src was highly elevated in a W300A
mutant yeast strain due to a 10-fold increase in cellular protein levels of the kinase. In contrast, the cellular
activity of GR remained almost unaffected by the W300A mutation but was dramatically sensitive to S485Y and
T525I exchanges. In addition, we show that mutations S485Y and T525I in Hsp90M reduce the ATP hydrolysis
rate, suggesting that Hsp90 ATPase is more tightly regulated than assumed previously. Therefore, the acti-
vation of GR and v-Src has various demands on Hsp90 biochemistry and is dependent on separate functional
regions of Hsp90M. Thus, Hsp90M seems to discriminate between different substrate types and to adjust the
molecular chaperone for proper substrate activation.
Heat shock protein 90 (Hsp90) is a highly conserved, abun-
dant and constitutively expressed homodimeric molecular
chaperone of the eukaryotic cytosol. It is specifically involved
in the folding and conformational regulation of a limited sub-
set of client proteins. Many natural substrates of Hsp90 are
medically relevant signal transduction molecules, e.g., the nu-
clear receptors for steroid hormones and several kinases, some
of them with oncogenic potential (19, 23, 24). To fulfill its
biological function, Hsp90 cooperates with different cochaper-
ones, such as Hop, p50, p23, Aha1, the immunophilins, and
others, and acts as part of a multichaperone machine together
with Hsp70.
Hsp90 is composed of a N-terminal nucleotide binding do-
main (Hsp90N), a middle domain (Hsp90M), and a C-terminal
domain (Hsp90C) that mediates the dimerization of the pro-
tein. A hallmark of the Hsp90 reaction cycle is binding and
hydrolysis of ATP (20, 21, 26, 34). Although the catalytic cen-
ter for this reaction has been identified within the N-terminal
domain of the protein, the interplay between this part and the
other domains of Hsp90 during substrate activation is poorly
understood. Emerging evidence suggests that the middle do-
main of Hsp90 plays an important role in this process. For
example, it has been shown that Hsp90M interacts with Aha1,
a cochaperone that stimulates Hsp90’s rate of ATP hydrolysis
and increases the efficiency of client protein activity (8, 11, 22).
Moreover, communication between the middle and N-terminal
domains of Hsp90 is essential in vivo (13), probably due to the
role of a Hsp90M segment in the proper orientation of the
-phosphate group of ATP for hydrolysis by the N-terminal
catalytic domain (15). Furthermore, a peptide spanning 14
amino acid residues within Hsp90M has been suggested as the
binding site for a natural client protein (30). Several point
mutations within Hsp90M that exhibit temperature-sensitive
growth defects in Saccharomyces cerevisiae have been identified
by yeast genetic methods (2, 9, 19) or proposed and generated
based on the recent crystal structure of this domain (15).
Hence, a comprehensive analysis of these point mutations with
regard to ATP hydrolysis rate, binding of cochaperones, and
activation of natural Hsp90 client proteins in vivo should in
turn yield information on the “normal” function of the middle
domain of Hsp90 and the sites therein affected by these mu-
tations.
We created site-directed exchanges W300A, E381K, E431K,
S485Y, T525I, and the triple mutant F329A/L331A/F332A in
Hsp90. The phenotypes of the respective yeast strains and the
underlying biochemistry of mutant Hsp90 proteins were com-
pared to mutations T22I and T101T that are located in the
catalytic N-terminal domain and cause a general reduction of
client protein activity due to their hyper- or hypoactive ATP
hydrolysis rate. As a result, we find that v-Src and glucocorti-
coid receptor (GR), representing two major classes of Hsp90-
dependent substrate proteins, are affected in different ways by
mutations in the middle domain of Hsp90. This result suggests
a role for Hsp90M in discriminating between various types of
client proteins during their processes of activation. Moreover,
we observed that the ATPase activity of the molecular chap-
erone Hsp90 is sensitive to segments within the middle domain
of Hsp90 that are essential for GR activation but not involved
in communication between Hsp90N and Hsp90M domains.
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MATERIALS AND METHODS
Plasmid construction and yeast two-hybrid experiments. Yeast Hsp90 was
amplified from plasmid pTGPD/P82 (19), and the yeast cochaperones Aha1, p23
(Sba1), Hop (Sti1), and p50 (Cdc37) were amplified from wild-type yeast DNA.
PCR products were inserted into the bacterial expression vector pProExHTa to
generate an amino-terminal His6 sequence followed by a tobacco etch virus
cleavage site. For expression in yeast cells, cochaperones were cloned into
pYX122. The pYX122 vector is an autonomously replicating low-copy plasmid (1
to 5 copies per cell) for the expression of proteins under the control of the strong
triose phosphate isomerase promoter. Point mutations T22I, T101I, W300A,
E381K, E431K, S485Y, T525I, and the triple mutation F329A/L331A/F332A
were inserted into the yeast vector pTGPD/P82 or into Hsp90 in the bacterial
pProExHTa expression vector by using a QuikChange site-directed mutagenesis
kit (Stratagene) with missense oligonucleotides. Desired exchanges were con-
firmed by DNA sequencing.
Protein purification and protein interaction assays. Expression constructs in
pProExHTa were transformed into Escherichia coli BL21(DE3)pLysS cells. Bac-
teria were grown at 18°C in LB medium supplemented with 100 mg/liter ampi-
cillin and 34 mg/liter chloramphenicol to an optical density at 600 nm (OD600) of
1, and protein expression was induced for 5 h with 0.25 mM IPTG (isopropyl-
-D-thiogalactopyranoside). After harvesting, proteins were enriched from cell
pellets by nickel-nitrilotriacetic acid chromatography at pH 8.0 essentially as
described previously (20). Proteins were further purified by ion-exchange fast-
performance liquid chromatography using ResourceQ columns or by gel filtra-
tion using Superose12 (Amersham Biosciences). For gel filtration analysis,
500-l samples containing the indicated combinations of yeast protein Hsp90,
Aha1, p23, Hop, or p50 (each at 5 M) in 40 mM HEPES-KOH (pH 7.4), 100
mM KCl, and 2 mM MgCl2 were incubated for 10 min and separated at 4, 25, or
37°C as indicated in Fig. 3 with a Superose12 column equilibrated in the same
buffer and using an A´KTA chromatography system (Amersham Biosciences).
When p23 was analyzed for interaction with Hsp90, 2 mM ATPS was added (8).
Fractions of 500 l were collected for analysis beginning at a 6-ml elution
volume. To quantify cochaperone binding, Coomassie-stained sodium dodecyl
sulfate (SDS) gels were analyzed with a Bio-Rad ChemiDoc XRS system, and the
binding of p23 or Aha1 to Hsp90 was determined as the percent ratio between
cochaperone and Hsp90 in fractions 6 to 11.
Assay of Hsp90 ATPase activity. Recombinant wild-type or mutant Hsp90
proteins (5 M) were incubated at 25 and at 37°C with or without the addition
of Aha1 (5 M) in 40 mM HEPES-KOH (pH 7.4) and 2 mM MgCl2 supple-
mented with 2 mM [-32P]ATP (4 Ci/mM; Amersham Biosciences) for 15 min
in a final volume of 20 l. Aliquots of each reaction were stopped at time points
by the addition of 5 mM EDTA and freezing in liquid nitrogen (20). The
separation of ADP from ATP was achieved by thin-layer chromatography on
polyethyleneimine-cellulose sheets (Merck) in 0.5 M LiCl and 0.5 M formic acid.
ATPase activity was monitored by quantitation of [-32P]ADP by using a liquid
scintillation counter. Steady-state ATPase rates were calculated from the linear
range of the reactions, and the ATP hydrolysis activity of 5 M wild-type Hsp90
at 25°C was set to 100%. Inhibition of the ATPase activity by geldanamycin
ensured the specificity of the measurement (20).
Yeast methods and manipulation. Yeast strain PCLDa/ (19) was used
throughout this study, and standard methods for growth and transformation were
employed. Cells were cultured on yeast extract-peptone-dextrose (YPD) medium
or on SD, SRaf, or SGal selective minimal medium (0.67% yeast nitrogen base
supplemented with 2% glucose, raffinose or galactose, respectively, and with
nucleotides and amino acids depending on auxotrophy). Intrinsic wild-type
Hsp90 of PCLDa/ on the URA3-containing pKAT6 plasmid was replaced by
a Hsp90 mutant gene or by wild-type Hsp90 on the expression vector pTGPD/
P82 (19) by the plasmid shuffling technique as described previously (20, 32).
Expression and detection of v-Src in yeast cells. After plasmid shuffling, yeast
strains were transformed with Y316v-Src. Cells were selected on SD medium
lacking Ura (SD-Ura medium), grown overnight in SRaf-Ura medium, diluted to
an OD600 of 0.2, and grown on SGal-Ura medium for 6 h at 25°C to induce v-Src
expression. For preparation of cell lysates, cultures were collected by centrifu-
gation, resuspended in lysis buffer (8 M urea, 5% [wt/vol] sodium dodecyl sulfate,
40 mM Tris-HCl [pH 7.5], 0.1 mM EDTA) (28) and treated by ultrasonification
for 5 s on ice. For immunoblotting, antibodies 4G10 (Upstate) and EC10 (Up-
state) were used to detect phosphotyrosine residues and v-Src protein, respec-
tively. Duplicates of samples were run on Coomassie-stained gels and served as
loading controls. An ECL reagent kit (Amersham Biosciences) was used to
visualize immunocomplexes. Quantification of blots and gels was performed with
a Bio-Rad ChemiDoc XRS system using the Quantity One software package, and
immunosignals were normalized to the protein content of the loading control.
Determination of GR activity in yeast cells. For analysis of GR activity, yeast
cells were transformed with the GR-expressing plasmid p2HGal/GR/CYC and
the reporter plasmid pSX26.1 expressing -galactosidase under the control of
GR response elements (19). Cells were grown on SRaf-His-Ura medium, and
GR synthesis was induced by shifting cultures to SGal-His-Ura medium. Recep-
tors were activated at an OD600 of 0.2 by the addition of 10  deoxycortico-
sterone (DOC) for 1 h, cells were collected by centrifugation, and -galactosi-
dase activity was measured using an GalactoStar kit (Tropix) and normalized to
the protein concentration of cell lysate that had been determined by the Bio-Rad
protein assay kit. The mouse monoclonal antibody BuGR2 (Affinity Bioreagents)
was used to detect levels of GR in yeast cell lysates, and quantification was
carried out as described for v-Src.
RESULTS
Point mutations in the middle domain of Hsp90 confer
growth defects. Missense mutations W300A, E381K, E431K,
S485Y, and T525I in the middle domain of Hsp90 (Fig. 1A)
have been identified by mutational analysis or deduced from
structural data (2, 9, 15, 19) and show temperature-sensitive
growth defects. Moreover, we generated the triple point mu-
tation F329A/L331A/F332A because the potential of a hydro-
phobic patch consisting of amino acids F329, L331, and F332
has been recently discussed in the literature with regard to its
impact on client protein activity (1, 15). For E431K and T525I,
variations in the ability to activate different subclasses of ste-
roid receptors (glucocorticoid receptor, progesterone receptor,
estrogen receptor, and mineralocorticoid receptor) have been
FIG. 1. Point mutations generated along the Hsp90 sequence and
resulting phenotypes for S. cerevisiae. (A) Schematic representation of
the domain organization of Hsp90. Positions of amino acid substitu-
tions refer to the sequence of yeast Hsc82. (B) Viability of mutant
yeast strains at 25 and 37°C. Shuffled cells were grown overnight in
YPD medium, adjusted to 1  108 cells per ml, and 10-fold serially
diluted. Two-microliter portions were spotted onto YPD agar plates
and incubated for 72 h at 25°C or for 48 h at 37°C. Boldface type
indicates cells with temperature-sensitive growth defects. WT, wild
type.
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reported (2). However, with the exception of E381K (19), the
consequences of the variety of Hsp90M mutations in handling
different types or families of client proteins, such as v-Src, a
kinase, or GR, a steroid receptor, have not been comparatively
analyzed. Interestingly, GR itself, when bound as a substrate to
Hsp90, can stimulate the ATPase activity of the molecular
chaperone (14).
Thus, we decided to compare exchanges in Hsp90M to wild-
type Hsp90 and to T22I and T101I, which are mutated in the
N-terminal catalytic domain of Hsp90, exhibit a temperature-
sensitive phenotype, and are reduced in the activation of het-
erologous client proteins v-Src and GR (19), probably due to
their hyper- or hypoactive intrinsic ATP hydrolysis rate (25).
Point mutations in Hsp90 were purified as recombinant pro-
teins for biochemical analysis or introduced into yeast cells by
plasmid shuffling to generate a system for in vivo analysis.
Phenotypes of the resulting strains are depicted at 25 and 37°C
and cells with temperature-sensitive growth defects are indi-
cated in Fig. 1B.
With respect to cell growth, client protein activation, or
ATPase activity, the F329A/L331A/F332A triple mutant be-
haved like the F332Q exchange that had been created to
introduce a polar amino acid into that hydrophobic patch
(15). Hence, it is unlikely that this hydrophobic patch plays
a central role in substrate binding, in agreement with pre-
vious results (15).
Intrinsic ATP hydrolysis rate of Hsp90 point mutants and
stimulation of their ATPase activity by Aha1. Defects of T22I
and T101I mutations in the N-terminal catalytic domain of
Hsp90 result from its ATPase hyper- and hypoactivity (Table
1) (25, 33). In addition, R380A and Q384A point mutations
that affect residues required for orientation of the -phosphate
of ATP for nucleophilic attack by the catalytic center in the
N-terminal domain of Hsp90 were identified in the middle
domain of Hsp90 (15). Therefore, mutations of residues of the
catalytic domain or those involved in communication between
the Hsp90N and the Hsp90M domain led to decreased ATPase
activity and compromised client protein activation (15). How-
ever, other segments of Hsp90M are not known to affect the
ATPase activity of the molecular chaperone (15). To analyze
Hsp90M further, we purified the Hsp90 point mutants indi-
cated above and tested their intrinsic ATP hydrolysis rate as
well as their susceptibility to Aha1 stimulation at 25 and at
37°C (Table 1). T22I or T101I, serving as a control, showed
increased or decreased intrinsic ATPase activities, respectively
(Table 1) (25, 33), and the T22I mutant displayed a reduced
response to Aha1-dependent ATPase stimulation, as reported
recently (33). In contrast, W300A, F329A/L331A/F332A, and
E381K exhibited no striking difference from wild-type Hsp90,
with ATPase stimulation by Aha1 being slightly decreased for
the W300A and E381K mutants (Table 1) (11). The mutations
E431K, S485Y, and T525I that map outside the contact region
between the N-terminal and the middle domain of Hsp90
showed compromised ATP hydrolysis rate at 25 and at 37°C,
an observation that had not been expected (15). The mutant
E431K was stimulated by Aha1 to wild-type ATPase activity at
25 and at 37°C (Table 1). In contrast, Aha1 stimulated S485Y
and T525I mutants up to the level of nonstimulated wild-type
Hsp90 at 25°C. At 37°C, however, Aha1 exerted no stimulation
on the low intrinsic ATPase activity of S485Y and T525I mu-
tants (Table 1).
Mutations W300A, S485Y, and T525I in the middle domain
of Hsp90 impair its interactions with the cochaperone p23 or
Aha1. Functional defects might be an intrinsic property of the
respective Hsp90 mutant or may result from compromised
interaction between Hsp90 and a particular cochaperone. To
investigate whether mutations in the middle domain impair
binding of Hsp90 to cochaperones, we used purified Hsp90 and
the cochaperones p23, Aha1, Hop, and p50 to test their inter-
action by gel filtration chromatography (8). Hop and p50 use
the C-terminal or N-terminal domain of Hsp90 for binding
and, hence, no difference was detected compared to the wild
type when their interaction with the various Hsp90M mutants
was tested (data not shown). Binding sites for p23 and Aha1
overlap on the middle domain of the Hsp90 chaperone, as
shown recently by crystal structure analysis of full-length
Hsp90 and by nuclear magnetic resonance analysis of Hsp90M
(1, 12). When we probed p23 for interaction with Hsp90M
mutants, binding to W300A appeared almost like that of the
wild type. The affinity of S485Y and T525I to p23 was strongly
reduced compared to other mutants or to wild-type Hsp90
(Fig. 2). This observation is supported by the finding that
immobilized p23 cannot pull out Hsp90 from S485Y and T525I
mutant strains (5). When the interaction to Aha1 was tested,
W300A, S485Y, and T525I exhibited reduced binding capacity
(Fig. 2). To analyze more rigorously the effects of Hsp90 mu-
tants on cochaperone binding, we performed a series of gel
filtration experiments at 4, 25, and 37°C. As a measure for
TABLE 1. Relative ATPase activity of Hsp90 mutantsa
Construct
ATPase activity at 25°C ATPase activity at 37°C
Unstimulated Aha1stimulated
Fold
stimulation Unstimulated
Aha1
stimulated
Fold
stimulation
Wild type 100 557 5.6 369 1,456 3.9
T22I 702 1,552 2.2 1,436 1,998 1.4
T101I 30 124 4.1 56 147 2.6
W300A 105 403 3.8 365 1,002 2.7
F329A/L331A/F332A 89 514 5.8 398 1,374 3.5
E381K 97 428 4.4 312 855 2.7
E431K 42 619 14.7 129 1,450 11.2
S485Y 31 122 3.9 121 104 0.9
T525I 43 133 3.1 132 176 1.3
a Values are given as percentages of results for the wild type.
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binding activity, the percent ratio of p23 and Aha1 shifted with
Hsp90 in fractions 6 to 11 was quantified at each temperature
(Fig. 3). Compared to wild-type Hsp90, binding of p23 was
reduced to about 4/5 for W300A and to about 1/10 for T525I,
and binding was negligible for S485Y (Fig. 3A) at each tem-
perature. Binding of Aha1 to W300A was modestly reduced
compared to wild-type Hsp90 at 25 and 37°C, consistent with
structural predictions (16), probably accounting for the lower
stimulation of W300A ATPase activity by Aha1 (Fig. 3B). The
S485Y and T525I exchanges further reduced binding of Aha1
to Hsp90 to about 1/5 to 1/10 of that of the wild type, depend-
ing on the mutation (Fig. 3B), which may explain the decreased
stimulation of ATPase activity of these mutants by Aha1 at
25°C (Table 1). However, binding of Aha1 to S485Y and T525I
mutants is not further compromised by raising the temperature
to 37°C (Fig. 3B). Thus, failure of ATPase stimulation most
probably results from a temperature-dependent defect of the
Hsp90 protein itself at 37°C rather than from impaired binding
of Aha1. Despite the lower cochaperone binding strength of
S485Y and T525I yeast strains, their growth was not impaired
at 25°C, and growth defects could be detected only at the
elevated temperature of 37°C. W300A showed a dramatic
FIG. 2. Interaction of p23 and Aha1 with middle domain mutants of Hsp90. Purified p23 (left panel) and Aha1 (right panel) as well as wild-type
(WT) and mutant Hsp90 proteins were incubated as indicated and fractionated by gel filtration chromatography on a Superose12 column. Fractions
were analyzed by SDS-polyacrylamide gel electrophoresis. Marker proteins are shown on top (thyroglobulin, 669 kDa; bovine serum albumin, 67
kDa). In the case of p23, a negative control in the absence of p23 (w/o) is included.
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FIG. 3. Quantification of Hsp90 middle domain mutants binding to Aha1 and p23 at 4, 25, and 37°C. Protein complexes of p23 or Aha1 with Hsp90
wild-type and mutant proteins were formed and fractionated by gel filtration chromatography at different temperatures as indicated. Quantification of
Coomassie-stained SDS gels was performed using a Bio-Rad ChemiDoc XRS system with the Quantity One software package. Binding activity was
determined as the percent ratio of bound p23 or Aha1 versus Hsp90 protein in fractions 6 to 11. One representative gel per experiment is shown. For
quantification, experiments were repeated three times, and the error bars show the standard deviations for the three experiments. (A) Quantification of
p23 binding to Hsp90 wild type (WT) and Hsp90 mutants. (B) Quantification of Aha1 binding to Hsp90 wild type and Hsp90 mutants.
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growth defect even at 25°C and was not viable at 37°C (Fig.
1B). As ATPase activity and stimulation by Aha1 is only mildly
affected, impaired cochaperone binding seems to be only a
minor contribution to the defects of this mutant but does not
account for its major defects. Therefore, proper binding of p23
and Aha1 appears to be not a general requirement for cell
viability but might be important for specific functions of Hsp90.
This view is supported by the fact that deletions of p23, Aha1,
and Hop are tolerated by yeast cells under normal conditions
(5, 7, 11).
Cellular activity of the heterologous client protein v-Src is
highly sensitive to the W300A mutation in the middle domain
of Hsp90. Mutations T22I and T101I in Hsp90N interfere with
the ATPase cycle of the molecular chaperone, resulting in a
general loss of Hsp90-dependent client protein activity that
affects GR and v-Src equally (19, 25). For some point muta-
tions mapping to the middle domain of Hsp90, the activity of
either GR or v-Src has been analyzed (2, 9, 19). However, no
systematic approach has been applied to elucidate whether
these mutations affect both client proteins equally or whether
differences between GR and v-Src activation arise. Thus, we
tested W300A, F329A/L331A/F332A, E381K, E431K, S485Y,
and T525I at 25°C for their ability to activate v-Src and GR and
to compare their defects in activating both kinds of client
proteins. v-Src activity was low in T22I and T101I strains and in
the E381K mutant as reported previously (19), whereas the
v-Src activity of the triple mutant F329A/L331A/F332A, as well
as of E431K, S485Y, and T525I, was only moderately affected
in vivo (Fig. 4). Surprisingly, the W300A mutant was hyperac-
tive in v-Src activation (Fig. 4A). In contrast, the W300A mu-
tation led to minor activity of the client protein v-Src when
grown at 30°C (Fig. 4B) (15). Hence, the W300A exchange
results in a temperature-sensitive functional frailty of a seg-
ment of the Hsp90 middle domain that is very critical for v-Src
activation.
Cellular activity of heterologous Hsp90 client proteins GR
and v-Src responds differently to mutations in the middle
domain of the molecular chaperone. When GR was tested, a
dramatic loss of activity was observed for T22I and T101I,
similar to the effect of these mutants on v-Src activity (Fig. 5A).
In contrast to its effect on v-Src activity, the W300A exchange
had only a minor effect on GR at 25 and at 30°C and still
exhibited 	60% of wild-type activity (Fig. 5A and B) at both
temperatures. The triple mutant F329A/L331A/F332A af-
fected neither v-Src activity nor GR activity significantly. This
result suggests that loss of hydrophobicity in this patch has no
major impact on client protein activity and, as substrate pro-
teins enter Hsp90 in a prefolded, close-to-native state, they
might not primarily bind to exposed hydrophobic side chains of
Hsp90 (35). In contrast, the E381K mutation resulted in neg-
ligible activity for kinase and hormone receptor activity (Fig.
5C). E431K, S485Y, and T525I mutations are outside the con-
tact region between Hsp90N and Hsp90M (15). The three
mutations have a moderate effect on v-Src activity, lowering it
to 	50 to 75% of that of the wild type (Fig. 4C and 5C), but
show a massive impairment of GR activity (Fig. 5A and C).
Taken together, these results indicate that W300A strongly
affects cellular activity of v-Src kinase but compromises GR
hormone receptor activity only moderately (Fig. 5C). The
E431K, S485Y, and T525I mutants, however, showed minor
effects on v-Src activity but a dramatic loss of GR activity (Fig.
5C). From these results, it is reasonable to conclude that sub-
strate activation of the two types of Hsp90-dependent client
proteins, v-Src and GR, has different demands on the biochem-
FIG. 4. Point mutations in the sequence of the middle domain of Hsp90
interfere with the activation of the Hsp90-dependent client proteins v-Src.
(A) Cell lysates were prepared from normal or mutant PCLDa/ strains
expressing v-Src or from empty vector control cells (pRS316) grown at 25°C
as described in Materials and Methods. Proteins were separated by poly-
acrylamide gel electrophoresis on 7.5% gels and transferred to nitrocellulose
membranes. Phosphotyrosine activity was monitored by Western blot analysis
with antibody 4G10. Quantification of protein load was performed with a
Bio-Rad ChemiDoc XRS system as described in Materials and Methods and
used for normalization of phosphotyrosine activity. One representative blot
and gel out of three independent experiments are shown. (B) Phosphoty-
rosine activity of control cells (pRS316) and of wild-type and W300A cells
grown at 30°C. (C) Quantification of v-Src-dependent phosphotyrosine levels
from the Western blots shown in panel A. Error bars show the standard
deviations from the means for the three experiments. The activity of wild-type
(WT) cells was set to 100%.
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istry of the molecular chaperone. Thus, Hsp90 may use indi-
vidual mechanistic routes to activate the various kinds of client
proteins, as demonstrated for the examples of v-Src and GR in
this study.
Mutations in the middle domain of Hsp90 affect steady-state
levels of v-Src and GR differently. In order to examine different
client protein handling by Hsp90 further, steady-state levels of
client proteins v-Src and GR were monitored and quantified in
yeast cells by Western blotting using specific antibodies (Fig. 6;
Table 2) (19, 28). When v-Src accumulation was analyzed, only
F329A/L331A/F332A exhibited near wild-type levels, while in
most other mutants, v-Src was reduced (Fig. 6A). However, a
dramatic increase of v-Src levels was detected in the W300A
mutant, which seems to account for some of the properties of
this strain (Fig. 6A). The accumulation of GR reached wild-
type levels for most mutants, with the exception of T22I (19)
and the middle domain mutants E381K and E431K (Fig. 6B).
Interestingly, most Hsp90M mutations affected steady-state
levels of v-Src and GR differently. For example, v-Src accumu-
lation in T101I, E381K, S485Y, and T525I strains was lower
than in wild-type cells but tremendously elevated in the
W300A strain at 25°C (Fig. 6A). Conversely, GR accumulation
was low in T22I, E381K, and E431K strains (Fig. 6B). To
evaluate whether cellular protein levels or specific activity of
the substrate are mainly affected by the various Hsp90 mutants,
we determined specific client protein activities as a quotient of
cellular activity (as measured by phosphotyrosine or -galac-
tosidase activity) and cellular levels of protein accumulation
(Table 2). T101 and E381K reduce cellular activity as well as
specific activity of v-Src and GR to similar levels, suggesting
FIG. 5. GR and v-Src activity in wild-type and mutant Hsp90 yeast strains. Mutant and wild-type strains were cotransformed with GR and the
reporter plasmid pSX26.1 containing -galactosidase under the control of GR response elements. GR was activated by the addition of 10 M DOC
as described in Materials and Methods. GR-dependent -galactosidase activity was measured using a GalactoStar kit (Tropix) and normalized to
the protein concentration of the lysate. Activities are averages from at least five independent experiments, and error bars are indicated. The
background activity of expressed but not DOC-activated GR was subtracted, resulting in lower specific activities than those reported in previous
studies (19). (A) GR activity in wild-type and indicated mutant strains grown at 25°C. (B) GR activity in wild-type and W300A strains measured
at 30°C. (C) v-Src and GR activity measured for wild-type and mutant yeast strains at 25°C. Activity of the wild-type (WT) strain was set to 100%.
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that v-Src and GR are equally dependent on general Hsp90
function (Table 2). The specific activities of GR and v-Src
respond similarly to W300A, whereas this mutant leads to a
10-fold accumulation of v-Src protein compared to wild-type
cells and hence enhanced cellular kinase activity. Obviously,
W300A increases cellular activity of v-Src basically by enhanc-
ing the accumulation of the protein, while it does not affect
steady-state protein levels of GR. E431K is reduced by GR
accumulation but confers wild-type-like specific activity to GR.
S485Y and T525I mutants affect v-Src and GR differently.
Although the accumulation of v-Src is decreased, the specific
activity of v-Src is even higher in both strains than in the wild
type. On the other hand, S485Y and T525I mutations lead to
GR accumulation at almost wild-type levels, but the receptor
fails to attain activity. This suggests that v-Src and GR are
dependent on different specific biochemical properties located
along the middle domain of Hsp90. Moreover, our study shows
that E431K on one hand and S485Y and T525I exchanges on
the other hand have different consequences on the biochem-
istry of Hsp90, a result which can explain the observation that
E431K specifically impairs GR activity, whereas S485Y and
T525I affect all steroid receptors (2). Hence, it is tempting to
speculate that the basic biochemical requirements for hormone
receptor activation are located within an area covered from
S485 through T525 on the Hsp90 protein.
Compromised GR activity in S485Y and T525I mutants can
be rescued in part by overexpression of p23. The activity of
v-Src and GR is sensitive to Hsp90 mutations W300A or
S485Y and T525I, respectively (Fig. 5C), and the yeast mutants
exhibit temperature-dependent growth defects (Fig. 1B). We
therefore asked whether these defects can be rescued by the
overexpression of Hsp90 cochaperones. As none of the co-
chaperones, Aha1, Hop, p50, or p23, could rescue the W300A
mutant strain (data not shown), the deficiencies caused by this
exchange seem to originate from intrinsic failures. In contrast,
the overexpression of p23 and Hop, but not of Aha1 or p50, in
S485Y and T525I partially rescued their growth defects at 37°C
(Fig. 7A). When these two mutants were assessed for rescue of
GR activity, p23 but neither Hop, Aha1, nor p50 overexpres-
sion led to a severalfold increase of -galactosidase reporter
activity; GR activity was never fully restored but reached about
12% of wild-type levels in the T525I strain (Fig. 7B). This
finding supports the view that S485Y and T525I compromise
Hsp90 biochemistry in more than p23 binding and stresses the
specific roles of the segment encompassing S485 to T525 and
of the cochaperone p23 in the assembly of Hsp90 complexes
with GR (4, 10, 17, 18).
FIG. 6. Steady-state expression levels of Hsp90-dependent client pro-
teins v-Src and GR in wild-type and mutant yeast strains. Quantification
was performed with a Bio-Rad ChemiDoc XRS system using the Quantity
One software package and normalized to the protein content of loading
controls. A typical blot for v-Src and GR levels is shown, and experiments
were done in triplicate for quantification. Data were used to calculate
specific activity of v-Src and GR as presented in Table 2. (A) Cell lysates
from v-Src expressing yeast (same as in Fig. 4A, see that figure legend for
loading control) were blotted for v-Src protein levels using the specific
monoclonal antibody EC10. (B) Cell lysates from GR-expressing yeast
were blotted for GR protein levels using the specific monoclonal antibody
BuGR2. Loading controls are shown on the bottom. WT, wild type.
TABLE 2. Activity and accumulation of v-Src and GR in mutant Hsp90 yeast strainsa
Yeast strain
Result for:
v-Src GR
Cellular activity Accumulation Sp act Cellular activity Accumulation Sp act
Wild-type 100 100 100 100 100 100
T22I 11.6 83.5 
 11.9 13.9 1.1 11.7 
 1.0 9.4
T101I 0.3 23.8 
 9.4 1.3 0.2 115.6 
 21.0 0.2
W300A 389.9 926.1 
 84.0 42.1 61.4 118.0 
 26.2 52.0
F329A/L331A/F332A 67.7 94.9 
 8.4 71.3 71.4 77.9 
 29.7 91.7
E381K 1.6 20.5 
 2.8 7.8 0.8 10.9 
 2.8 7.3
E431K 60.8 149.7 
 52.7 40.6 9.1 7.9 
 2.6 115.2
S485Y 40.4 26.6 
 4.8 151.9 0.3 77.3 
 13.0 0.4
T525I 76.8 28.7 
 18.9 267.6 1.6 102.7 
 15.6 1.6
a Values are given as percentages of results for the wild type.
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DISCUSSION
Hsp90 has been established as a nucleotide-dependent chap-
erone, and the mechanism of ATP hydrolysis on the molecular
level has been resolved (15, 20, 21, 26, 29, 34). Yet, how energy
created by the hydrolysis of ATP within the N-terminal domain
of Hsp90 is used for a conformational change within the client
protein to reach its native state remains enigmatic. Approaches
using classical chaperone substrates like firefly luciferase, rho-
danese, or citrate synthase suggested binding of the substrate
protein to the N- and C-terminal domains of Hsp90 (31, 36).
Recent studies, however, using natural substrate proteins of
Hsp90 propose instead that the middle domain of the molec-
ular chaperone plays a role in client protein binding (6, 30).
Therefore, Hsp90M may have a central position in substrate
recognition, distinguish between different kinds of substrates,
and adjust the molecular chaperone to the demands for acti-
vation of a specific client protein. To gain insight into the
function of Hsp90M and to figure out whether activation of all
kinds of substrates follows a general route or whether different
client proteins have distinct demands on specific Hsp90 func-
tions, we used a series of Hsp90 point mutations. For analysis,
we focused on the activity of Hsp90-dependent substrates v-Src
FIG. 7. Effect of cochaperone overexpression on the viability and client protein activity of Hsp90 mutant strains S485Y and T525I. (A) S485Y
and T525I strains were cotransformed with empty vector serving as a control or p23, Hop, Aha1, and p50 expression plasmids. Pictures were taken
from different plates that had been incubated together at 37°C. (B) GR activity measured for wild-type and mutant yeast strains cotransformed
with empty vector, p23, Hop, Aha1, or p50 expression plasmids. Activity of the wild-type (WT) strain was set to 100%.
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and GR in vivo, as well as on underlying functional properties,
such as ATPase activity and the interaction with Hsp90 co-
chaperones. Some constraints of Hsp90 biochemistry affected
v-Src and GR activity equally. The mutation T101I in the
N-terminal catalytic domain that interferes with the ATP hy-
drolysis cycle of Hsp90 (27) and the E381K mutation in the
middle domain both result in a general impairment of client
protein activity in the cell. Some other mutations in the middle
domain of Hsp90, however, showed diverse biochemical defi-
cits, had different capacities to activate v-Src and GR, and
seem therefore to be capable of discriminating between
Hsp90-dependent client proteins.
W300A is located adjacent to a region (amino acids 327 to
340) that was proposed to serve as the binding region for
kinase substrates (30) and forms part of a conformationally
flexible loop with an amphipathic structure (15). On the atomic
level, W300 makes a hydrophobic interaction with a “shallow
hydrophobic recess on the outer face of Aha1” (16), which may
explain the observation that the W300A exchange slightly de-
creases the affinity of Hsp90 to this cochaperone. Our results
show that cellular v-Src activity is highly sensitive to this point
mutation at 25 and at 30°C, whereas GR activity was only
barely affected by the W300A exchange. Since ATPase activity
as well as binding to and stimulation by Aha1 were only a little
affected by the W300A mutation, other aspects of Hsp90 bio-
chemistry that affect v-Src activation may be altered. When we
analyzed steady-state levels of client proteins in the yeast cy-
tosol, it turned out that v-Src but not GR accumulation was
conspicuously elevated in W300A cells, while this mutation
affected the specific activity of both client proteins similarly. As
W300 is in close neighborhood to the loop for kinase binding
but not a part of this segment (30), it seems that W300 might
be critical for the control of v-Src loading on Hsp90 or for v-Src
release from Hsp90. Although higher accumulation of v-Src
results in a higher phosphotyrosine activity at 25°C in the
W300A strain, such a charge may block the Hsp90 chaperone
system for other substrate proteins (3). This effect might gain
the upper hand at 30°C, decrease the already low vitality of
W300A cells and, as a consequence, lead to a loss of v-Src
activity.
Exchanges S485Y and T525I resulted in moderately abridged
cellular v-Src activity but disturbed cellular GR activity almost
completely, strongly reduced binding of Hsp90 to p23 and
Aha1, and harmed the ATPase activity of the molecular chap-
erone. While the specific activity of GR in these mutant strains
was reduced to 	1%, the specific activity of v-Src was even
higher than in the Hsp90 wild-type strain. S485Y and T525I
map to the small  middle-segment domain encompassing
residues 435 to 525 of Hsp90’s middle domain that interacts via
ion pairs with Aha1 (1, 15, 16). Although not directly involved
in these interactions, mutations S485Y and T525I interfere
with Hsp90 binding to Aha1 either by altering the local con-
formation of this segment or by adding hydrophobicity to the
region and thus obstructing the formation of polar contacts.
Ali et al. (1) report in their recent atomic structure of full-
length Hsp90 that “the interface between the C domain and
the small middle-segment domain flexes on going from the
unconstrained M-C structure to the ATP-bound conformation,
bringing the small middle domains about 10 Å closer together.
This displaces the projecting helix-strand segments, which tilt
downwards and become less well ordered.” Since cochaperone
binding to Hsp90 and Hsp90 ATPase activity are affected by
the S485Y and T525I mutations, the conformational change
described above could be an additional mode to regulate
Hsp90 activity. Therefore, our biochemical data are comple-
mentary to the structural data and identify the small 
middle domain as part of a structural element with impact on
the ATPase reaction cycle of the molecular chaperone. How-
ever, it remains to be elucidated by molecular dynamics studies
how the movement of the middle-segment domains mech-
anistically affects the ATPase reaction, which is controlled by
the N-terminal domain together with an additional catalytic
loop in the large middle segment (15).
We have shown that v-Src and GR have different demands
on Hsp90 biochemistry and that their activity is affected dif-
ferently by point mutations in the middle domain of Hsp90.
Thus, it is plausible to suggest that the working mechanism of
Hsp90 is not a unique process but is dependent on the type of
substrate protein to be processed. As different kinds of cochap-
erones contribute to the efficiency of substrate activation, they
might regulate the Hsp90 core chaperone for tuning different
intrinsic activation programs for substrate proteins that can be
executed by the molecular chaperone.
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